Bushu Pharmaceutical Co., Ltd. hereby announces that it has decided on the following change in President & CEO, contingent upon the resolutions to be adopted at the Annual General Meeting of Shareholders and the Board of Directors meeting scheduled for June 29, 2026. This change follows the conclusion of Tadao Takano’s term of office as President & CEO.

Outgoing Executive：
President & CEO
Tadao Takano

Incoming Executive：
Senior Executive Vice President & CFO
Tetsuya Morikawa (Scheduled to assume the position of President & CEO)

Tetsuya Morikawa joined the Company in 2017 and has since played a central role in business operations and the promotion of company-wide strategy as Senior Executive Vice President & CFO. The Company has determined that this transition will establish the optimal leadership structure for achieving sustainable growth in the years ahead.
The Company remains firmly committed to uniting all employees in meeting the diverse needs of our customers. We will continue to deliver high‑quality services and solutions and contribute to society. We sincerely appreciate your continued support and partnership.

Contact for Inquiries
Human Resources/Legal & General Affairs Division
Keiichi Yanuma
Tel: +81 49-233-4651

About Bushu Pharma
Bushu Pharma is one of Japan’s leading CDMOs, leveraging more than 25 years of experience and expertise in contract development and manufacturing. We provide optimal solutions across solid dosage formulation and packaging, injectable manufacturing and packaging, technology transfer within Japan, production, packaging, logistics, and support from project initiation through regulatory approval.
For more information, please visit bushu-pharma.com.

CDMO (Contract Development and Manufacturing Organization):
A business that provides comprehensive manufacturing and development services to pharmaceutical companies, including contract manufacturing of pharmaceuticals, production of investigational drugs during development, and optimization of manufacturing conditions.